What are the latest figures on the remdesivir market’s size and projected CAGR?
The remdesivir market size has grown exponentially in recent years. It will grow from $6.49 billion in 2024 to $8.52 billion in 2025 at a compound annual growth rate (CAGR) of 31.2%. The growth in the historic period can be attributed to increasing prevalence of COVID-19, rising awareness of remdesivir, government support for remdesivir, clinical trials and research, government purchases.
The remdesivir market size is expected to see rapid growth in the next few years. It will grow to $15.91 billion in 2029 at a compound annual growth rate (CAGR) of 16.9%. The growth in the forecast period can be attributed to ongoing COVID-19 response, emerging variants, global vaccination campaigns, pandemic preparedness, global health initiatives. Major trends in the forecast period include personalized medicine, combination therapies, production scalability, telemedicine and remote monitoring, research on new indications, alternative antiviral therapies.
Get Your Free Sample of The Global Remdesivir Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3253&type=smp
Which Market drivers have played a significant role in driving the remdesivir market?
The increasing government expenditure is expected to propel the growth of the remdesivir market going forward. Government expenditure, also known as government spending, refers to the total amount of money that a government or public sector entity allocates and disburses to finance its operations, programs, services, and projects. Government expenditure is instrumental in the growth and accessibility of Remdesivir, especially during public health crises. By providing funding, regulatory support, purchasing power, and research investments, governments can contribute to the availability and affordability of this critical antiviral medication. For instance, in July 2023, according to the Government Digital Service, a UK-based government body, the central government’s own current spending on services increased from $876.47 billion to $963.74 billion in 2022–23. The amount spent on capital projects for services rose from $81.37 billion in 2021–2022 to $104.72 billion in 2022–2023 dollars. Therefore, the increasing government spending is driving the growth of the remdesivir market.
What are the key segments within the remdesivir market?
The remdesivir market covered in this report is segmented –
1) By Route Of Administration: Oral, Intravenous
2) By Dosage Form: Tablets, Frozen Solution, Lyophilized Solution
3) By Distribution Channel: Hospitals, Clinics, Drug Stores/Pharmacies, Online, Other Distribution Channels
Subsegments:
1) By Oral: Tablet Formulation, Liquid Formulation
2) By Intravenous: Ready-To-Use Injectable, Lyophilized Powder For Injection
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/remdesivir-global-market-report
Which key players are shaping the remdesivir market?
Major companies operating in the remdesivir market include Gilead Sciences Inc., BrightGene Bio-Medical Technology Co Ltd, Hainan Haiyao Co. Ltd., Sichuan Kelun Pharmaceutical Co. Ltd., Hunan Warrant Pharmaceutical, Cipla Limited, Pfizer Inc., Merck & Co. Inc., Cayman Chemical Company, Dr Reddy’s Laboratories Ltd., Inovio Pharmaceuticals, Shenzhen BORUI Pharmaceutical Technology Co. Ltd., Berry Global Group, Hetero Labs Limited, Mylan N.V., Zydus Cadila Health Care Limited, Syngene International Limited, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Teva Pharmaceutical Industries, Ferozsons Laboratories Limited, Jubilant Life Sciences, Laurus Labs, Macleods Pharmaceuticals, Natco Pharma, Sandoz Group AG, Strides Pharma Science Limited, Torrent Pharmaceuticals, Beximco Pharmaceuticals Ltd., Fresenius Kabi, Gland Pharma Limited, Hikma Pharmaceuticals, Lark Laboratories
How will evolving trends contribute to the growth of the remdesivir market?
The high cost associated with the drug is a key factor hampering the growth of the market. Gilead Sciences which produces remdesivir donates its initial supply of 1.5 million doses, but the company has demonstrated that it would have to begin charging the drug for sustainable production. There are various speculations on the pricing of the drug. According to the Institute for Clinical and Economic Review (ICER), the estimated price of Remdesivir would be between $4,580 to $5,080. The higher-end pricing of Remdesivir is expected to hinder the growth of the market.
How do regional factors impact the remdesivir market, and which region is the largest contributor?
North America was the largest region in the remdesivir market in 2024. Middle East is expected to be the fastest growing region in the remdesivir market report during the forecast period. The regions covered in the remdesivir market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
What Does The Remdesivir Market Report 2025 Offer?
The remdesivir market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Remdesivir refers to a class of drugs called antivirals that are used to treat hospitalized adults and children 28 days of age and older who weigh at least 6.6 pounds for COVID-19 disease 2019 (COVID-19 infection) caused by the SARS-CoV-2 virus (3 kg), who have a significant risk of developing severe COVID-19, which could result in hospitalization and death.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3253
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
